Elsevier Inc.

SHERPA: Unknown

People

  1. Shah
    Shah
  2. Giralt
    Giralt
  3. Devlin
    Devlin
  4. Scordo
    Scordo
  5. Perales
    Perales
  6. Landau
    Landau
  7. Dahi
    Dahi
  8. Chung
    Chung
  9. Hassoun
    Hassoun
  10. Lesokhin
    Lesokhin

Groups

  1. Bone Marrow Transplant (76)
  2. Center for Hematologic Malignancies (76)
  3. Department of Medicine (76)
  4. Epidemiology and Biostatistics (76)
  5. Hematologic Malignancies, Division of (76)
  6. Survivorship Research (76)
  7. Biostatistics Service (75)
  8. CTCR Scholars (61)
  9. MSK Grad Students (43)
  10. Master of Science in Clinical and Translational Cancer Research (42)
Search Within
  1. "Gunjan Shah"
  2. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (60)
  2. Journal Article (16)
Groups
  1. Bone Marrow Transplant (76)
  2. Center for Hematologic Malignancies (76)
  3. Department of Medicine (76)
  4. Epidemiology and Biostatistics (76)
  5. Hematologic Malignancies, Division of (76)
  6. Survivorship Research (76)

More Groups

People
  1. Gunjan Shah (76)
  2. Sergio Giralt (71)
  3. Sean Devlin (63)
  4. Michael Scordo (50)
  5. Miguel-Angel Perales (45)
  6. Heather Landau (33)

More People

Years
  1. 2024 (2)
  2. 2023 (12)
  3. 2022 (11)
  4. 2021 (3)
  5. 2020 (12)
  6. 2019 (8)

More Years

Publications
  1. Biology of Blood and Marrow Transplantation (44)
  2. Clinical Lymphoma, Myeloma and Leukemia (19)
  3. Transplantation and Cellular Therapy (11)
  4. International Journal of Radiation Oncology, Biology, Physics (1)
  5. eClinicalMedicine (1)

Results (76)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes and management of the SARS-CoV2 omicron variant in recipients of hematopoietic cell transplantation and chimeric antigen receptor T cell therapy
    Journal Article

    Infante, M. S.; Nemirovsky, D.; Devlin, S.; DeWolf, S.; Tamari, R.; Dahi, P. B.; Lee, Y. J.; Chung, D. J.; Politikos, I.; Barker, J.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • Reduced-intensity compared to nonmyeloablative conditioning in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic stem cell transplantation
    Journal Article

    Nath, K.; Peterson, K.; Brown, S.; Devlin, S.; Rodriguez, N.; Barker, J.; Giralt, S.; Gyurkocza, B.; Jakubowski, A.; Papadopoulos, E.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: The NUTRIVENTION trial
    Meeting Abstract

    Shah, U.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Hosszu, K.; Pollak, M.; Mailankody, S.; Korde, N.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Nath, K.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Vitamin D deficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save